vs
ANI PHARMACEUTICALS INC（ANIP）とRevolve Group, Inc.（RVLV）の財務データ比較。上の社名をクリックして会社を切り替えられます
Revolve Group, Inc.の直近四半期売上が大きい（$324.4M vs $247.1M、ANI PHARMACEUTICALS INCの約1.3倍）。ANI PHARMACEUTICALS INCの純利益率が高く（11.1% vs 5.7%、差は5.4%）。ANI PHARMACEUTICALS INCの前年同期比売上増加率が高い（29.6% vs 10.4%）。ANI PHARMACEUTICALS INCの直近四半期フリーキャッシュフローが多い（$29.1M vs $-13.3M）。過去8四半期でANI PHARMACEUTICALS INCの売上複合成長率が高い（34.1% vs 9.5%）
ANIファーマシューティカルズは米国に本社を置く特殊製薬会社で、後発医薬品とブランド処方薬の研究開発・製造・販売を行っています。主力製品分野は皮膚科、腫瘍、中枢神経系治療、感染症対策で、主に米国内の医療機関、調剤薬局、患者を対象としています。
Revolve Theatre Companyはテムズ河畔ヘンリーを拠点とする劇団で、政治的なテーマの作品やシェイクスピア劇を専門に制作・上演しており、オリバー・デンチ、ジョー・モリス、トム・スミスの3人が所有しています。
ANIP vs RVLV — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $247.1M | $324.4M |
| 純利益 | $27.5M | $18.6M |
| 粗利率 | — | 53.3% |
| 営業利益率 | 14.1% | 6.3% |
| 純利益率 | 11.1% | 5.7% |
| 売上前年比 | 29.6% | 10.4% |
| 純利益前年比 | 367.5% | 50.4% |
| EPS（希薄化後） | $1.14 | $0.27 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $247.1M | $324.4M | ||
| Q3 25 | $227.8M | $295.6M | ||
| Q2 25 | $211.4M | $309.0M | ||
| Q1 25 | $197.1M | $296.7M | ||
| Q4 24 | $190.6M | $293.7M | ||
| Q3 24 | $148.3M | $283.1M | ||
| Q2 24 | $138.0M | $282.5M | ||
| Q1 24 | $137.4M | $270.6M |
| Q4 25 | $27.5M | $18.6M | ||
| Q3 25 | $26.6M | $21.2M | ||
| Q2 25 | $8.5M | $10.2M | ||
| Q1 25 | $15.7M | $11.8M | ||
| Q4 24 | $-10.3M | $12.3M | ||
| Q3 24 | $-24.2M | $11.0M | ||
| Q2 24 | $-2.3M | $15.4M | ||
| Q1 24 | $18.2M | $10.9M |
| Q4 25 | — | 53.3% | ||
| Q3 25 | — | 54.6% | ||
| Q2 25 | — | 54.1% | ||
| Q1 25 | — | 52.0% | ||
| Q4 24 | — | 52.5% | ||
| Q3 24 | — | 51.2% | ||
| Q2 24 | — | 54.0% | ||
| Q1 24 | — | 52.3% |
| Q4 25 | 14.1% | 6.3% | ||
| Q3 25 | 15.9% | 7.1% | ||
| Q2 25 | 6.6% | 5.8% | ||
| Q1 25 | 13.3% | 5.0% | ||
| Q4 24 | -2.3% | 3.9% | ||
| Q3 24 | -13.8% | 5.0% | ||
| Q2 24 | 3.7% | 5.8% | ||
| Q1 24 | 14.8% | 3.4% |
| Q4 25 | 11.1% | 5.7% | ||
| Q3 25 | 11.7% | 7.2% | ||
| Q2 25 | 4.0% | 3.3% | ||
| Q1 25 | 8.0% | 4.0% | ||
| Q4 24 | -5.4% | 4.2% | ||
| Q3 24 | -16.3% | 3.9% | ||
| Q2 24 | -1.7% | 5.4% | ||
| Q1 24 | 13.2% | 4.0% |
| Q4 25 | $1.14 | $0.27 | ||
| Q3 25 | $1.13 | $0.29 | ||
| Q2 25 | $0.36 | $0.14 | ||
| Q1 25 | $0.69 | $0.16 | ||
| Q4 24 | $-0.45 | $0.18 | ||
| Q3 24 | $-1.27 | $0.15 | ||
| Q2 24 | $-0.14 | $0.21 | ||
| Q1 24 | $0.82 | $0.15 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $285.6M | $292.3M |
| 総負債低いほど良い | — | — |
| 株主資本純資産 | $540.7M | $512.5M |
| 総資産 | $1.4B | $765.0M |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $285.6M | $292.3M | ||
| Q3 25 | $262.6M | $315.4M | ||
| Q2 25 | $217.8M | $310.7M | ||
| Q1 25 | $149.8M | $300.8M | ||
| Q4 24 | $144.9M | $256.6M | ||
| Q3 24 | $145.0M | $252.8M | ||
| Q2 24 | $240.1M | $244.7M | ||
| Q1 24 | $228.6M | $273.4M |
| Q4 25 | $540.7M | $512.5M | ||
| Q3 25 | $505.8M | $490.2M | ||
| Q2 25 | $436.8M | $468.6M | ||
| Q1 25 | $418.6M | $453.4M | ||
| Q4 24 | $403.7M | $437.8M | ||
| Q3 24 | $405.9M | $420.8M | ||
| Q2 24 | $455.8M | $405.8M | ||
| Q1 24 | $452.0M | $389.9M |
| Q4 25 | $1.4B | $765.0M | ||
| Q3 25 | $1.4B | $751.3M | ||
| Q2 25 | $1.3B | $722.9M | ||
| Q1 25 | $1.3B | $713.9M | ||
| Q4 24 | $1.3B | $665.5M | ||
| Q3 24 | $1.3B | $670.9M | ||
| Q2 24 | $920.8M | $657.8M | ||
| Q1 24 | $914.5M | $650.0M |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $30.4M | $-10.2M |
| フリーキャッシュフロー営業CF - 設備投資 | $29.1M | $-13.3M |
| FCFマージンFCF / 売上 | 11.8% | -4.1% |
| 設備投資強度設備投資 / 売上 | 0.5% | 1.0% |
| キャッシュ転換率営業CF / 純利益 | 1.10× | -0.55× |
| 直近12ヶ月FCF直近4四半期 | $171.4M | $48.0M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $30.4M | $-10.2M | ||
| Q3 25 | $44.1M | $11.8M | ||
| Q2 25 | $75.8M | $12.6M | ||
| Q1 25 | $35.0M | $45.1M | ||
| Q4 24 | $15.9M | $3.9M | ||
| Q3 24 | $12.5M | $9.1M | ||
| Q2 24 | $17.4M | $-24.7M | ||
| Q1 24 | $18.3M | $38.4M |
| Q4 25 | $29.1M | $-13.3M | ||
| Q3 25 | $38.0M | $7.5M | ||
| Q2 25 | $71.8M | $10.4M | ||
| Q1 25 | $32.5M | $43.4M | ||
| Q4 24 | $13.5M | $2.1M | ||
| Q3 24 | $7.7M | $8.0M | ||
| Q2 24 | $13.0M | $-25.7M | ||
| Q1 24 | $13.7M | $36.7M |
| Q4 25 | 11.8% | -4.1% | ||
| Q3 25 | 16.7% | 2.5% | ||
| Q2 25 | 34.0% | 3.4% | ||
| Q1 25 | 16.5% | 14.6% | ||
| Q4 24 | 7.1% | 0.7% | ||
| Q3 24 | 5.2% | 2.8% | ||
| Q2 24 | 9.4% | -9.1% | ||
| Q1 24 | 10.0% | 13.5% |
| Q4 25 | 0.5% | 1.0% | ||
| Q3 25 | 2.7% | 1.5% | ||
| Q2 25 | 1.9% | 0.7% | ||
| Q1 25 | 1.3% | 0.6% | ||
| Q4 24 | 1.3% | 0.6% | ||
| Q3 24 | 3.2% | 0.4% | ||
| Q2 24 | 3.2% | 0.4% | ||
| Q1 24 | 3.3% | 0.6% |
| Q4 25 | 1.10× | -0.55× | ||
| Q3 25 | 1.66× | 0.56× | ||
| Q2 25 | 8.87× | 1.24× | ||
| Q1 25 | 2.23× | 3.82× | ||
| Q4 24 | — | 0.32× | ||
| Q3 24 | — | 0.83× | ||
| Q2 24 | — | -1.60× | ||
| Q1 24 | 1.00× | 3.53× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
RVLV
| Fashion Apparel | $155.1M | 48% |
| Dresses | $76.4M | 24% |
| Handbags Shoes And Accessories | $67.6M | 21% |
| Beauty | $20.3M | 6% |
| Manufactured Product Other | $5.0M | 2% |
| Breakage On Store Credit And Gift Cards | $900.0K | 0% |
